ATYR Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
ATYR Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
BRIEF — aTyr Pharma Announces Alignment With FDA On Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis
Sept 24 (Reuters) — aTyr Pharma Inc: Atyr Pharma Announces Alignment With Fda On Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis Atyr Pharma - To Initiate Study-related Activities In Q4 2026 Source text:... Further company coverage: ATYR.O (Reuters.Briefs@thomsonreuters.com;)
ATYR - aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
ATYR - aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis